Beneficial effects of angiotensin (1–7) in diabetic rats with cardiomyopathy

Therapeutic Advances in Cardiovascular Disease

Volumn 5, Issue 3, 2011, Pages 159-167

  Singh, Kulwinder ^a   Singh, Tajinder ^a   Sharma, P L ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

A 779; Angiotensin (1 7); Diabetic cardiomyopathy; Lipids; Mas receptor

Indexed keywords

ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; COLLAGEN; LIPID; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; NITRATE; NITRITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DENDRITIC CELL; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DYSLIPIDEMIA; FEMALE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE PRESSURE; HEART WEIGHT; LIPID BLOOD LEVEL; MALE; MEDICAL DOCUMENTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BLOOD GLUCOSE; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DYSLIPIDEMIAS; FIBROSIS; HEART VENTRICLES; HYPERTROPHY, LEFT VENTRICULAR; LIPIDS; NITRATES; NITRITES; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 79958752704     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944711409281     Document Type: Article

References (51)

1. Allain C.C. Poon L.S. Chan C.S.G. Richmond W. Fu P.C. (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20: 470–475.
2. Al-Maghrebi M. Benter I.F. Diz D.I. (2009) Endogenous angiotensin-(1–7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res 59: 263–268.
3. Benter I.F. Yousif M.H. Anim J.T. Cojocel C. Diz D.I. (2006) Angiotensin-(1–7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol 290: H684–H691.
4. Benter I.F. Yousif H.M. Anim J.T. Cojocel C. Diz D.I. (2007) Angiotensin-(1–7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 292: H666–H672.
5. Brenner B.M. Cooper M.E. de Zeeuw D. Keane W.F. Mitch W.E. Parving H.H. et al (2001) Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 345: 861–869.
6. Brownlee M. (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615–1625.
7. Castro C.H. Santos R.A. Ferreira A.J. Bader M. Alenina N. Almeida A.P. (2006) Effects of genetic deletion of angiotensin-(1–7) receptor Mas on cardiac function during ischemia / reperfusion in the isolated perfused mouse heart. Life Sci 80: 264–268.
8. Cheng L. Ding G. Qin Q. Huang Y. Lewis W. He N. et al (2004) Cardiomyocyte-restricted peroxisome proliferatoractivated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10: 1245–1250.
9. Chiu H.C. Kovacs A. Blanton R.M. Han X. Courtois M. Weinheimer C.J. et al (2005) Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Cir Res 96: 225–233.
10. Cho B.H.S. (1983) Improved enzymatic determination of total cholesterol in tissues. Clin Chem 29: 166–168.
11. Crackower M.A. Sarao R. Oudit G.Y. Yagil C. Kozieradzki I. Scanga S.E. et al (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417: 822–828.
12. Deepa P.R. Varalakshmi P. (2005) Beneficial cardio-renovascular effects of low-molecular-weight heparin-derivative on adriamycin-induced glycosaminoglycanuria and tissue lipid abnormalities. Toxicology 211: 77–85.
13. Devereux R.B. Roman M.J. Paranicas M. (2000) Impact of diabetes on cardiac structure and functions: The strong heart study. Circulation 101: 2271–2276.
14. Dirk W. Susanne R. Sebastian J. Anne L. Stefan A. Alexander R. et al (2007) Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy. Diabetes 56: 641–646.
15. Donoghue M. Hsieh F. Baronas E. Godbout K. Gosselin M. Stagliano N. et al (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Cir Res 87: E1–E9.
16. Ferrario C.M. Jessup J. Chappell M.C. Averill D.B. Brosnihan K.B. Tallant E.A. et al (2005 a) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605–2610.
17. Ferrario C.M. Jessup J. Gallagher P.E. Averill D.B. Brosnihan K.B. AnnTallant E. et al (2005 b) Effects of rennin–angiotensin system blockade on renal angiotensin-(1–7) forming enzymes and receptors. Kidney Int 68: 2189–2196.
18. Ferreira A.J. Santos R.A. (2005) Cardiovascular actions of angiotensin-(1–7). Braz J Med Biol Res 38: 499–507.
19. Ferreira A.J. Santos R.A.S. Almeida A.P. (2002) Angiotensin-(1–7) improves the post- ischemic function in isolated perfused rat hearts. Braz J Med Biol Res 35: 1083–1090.
20. Finck B.N. Han X. Courtois M. Aimond F. Nerbonne J.M. Kovacs A. et al (2003) A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 100: 1226–1231.
21. Folch J. Lees M. Sloane-Stanley G.H. (1957) A simple method for isolation and purification of total lipids from animal tissue. J Biol Chem 226: 497–509.
22. Giani J.F. Gironacci M.M. Munoz M.C. Pena C. Daniel T. Dominici F.P. (2007) Angiotensin-(1–7) stimulates the phosphorylation of JNK2, IRS-1 and Akt in rat heart in vivo: role of AT 1 and Mas receptors. Am J Physiol Heart Circ Physiol 293: H1154–H1163.
23. Giani J.F. Muñoz M.C. Mayer M.A. Veiras L.C. Arranz C. Taira C.A. et al (2010) Angiotensin-(1–7) improves cardiac remodeling and inhibits growth-promoting pathways in the heart of fructose-fed rats. Am J Physiol Heart Circ Physiol 298: H1003–H1013.
24. Gurley S.B. Allred A. Le T.H. Griffiths R. Mao L. Philip N. et al (2006) Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 116: 2218–2225.
25. Hamblin M. Frieddman D.B. Hill S. Richard M.C. Smith H.M. Hill M.S. (2007) Altrations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol 42: 884–895.
26. Harmer D. Gilbert M. Borman R. Clark K.L. (2002) Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 532: 107–110.
27. Herrero P. Peterson L.R. McGill J.B. Matthew S. Lesniak D. Dence C. et al (2006) Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 47: 598–604.
28. Iwata M. Cowling R.T. Gurantz D. Moore C. Zhang S. Yuan J.X.J. et al (2005) Angiotensin-(1–7) binds to specific receptors on cardiac fibroblasts to initiate anti-fibrotic and anti-trophic effects. Am J Physiol 289: H2356–H2363.
29. Jamall I.S. Finelli V.N. Que Hee S.S. (1981) A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 112: 70–75.
30. Jayasooria A.P. Mathai M.L. Walker L.L. Begg D.P. Denton D.A. Cameron-Smith D. et al (2008) Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci U S A 105: 6531–6536.
31. Leehey D.J. Singh A.K. Bast J.P. Singh R. (2008) Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats. Transl Res 151: 208–216.
32. Lowry O.H. Rosenberg A.L.F. Randall R.J. (1951) Protein measurement with folin phenol reagent. J Biol Chem 193: 265–275.
33. Miller J.A. Floras J.S. Zinman B. Skorecki K.L. Logan A.G. (1996) Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. Clin Sci 90: 189–195.
34. Nielsen L.B. Bartels E.D. Bollano E. (2002) Overexpression of apolipoprotein B in the heart impedes cardiac triglyceride accumulation and development of cardiac dysfunction in diabetic mice. J Biol Chem 277: 27014–27020.
35. Poornima I.J. Parikh P. Shannon R.P. (2006) Diabetic cardiomyopathy: the search for unifying hypothesis. Circ Res 98: 596–605.
36. Ruggenenti P. Mise N. Pisoni R. Arnoldi F. Pezzotta A. Perna A. et al (2003) Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 107: 586–592.
37. Sajad A.H. Billal P. Rajdeep S.K. Rayaz A.M. (2004) Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci 107: 539–557.
38. Sampaio W.O. Santos R.A.S. Faria-Silva R. Machado L.T.M. Schiffrin E.L. Touyz R.M. (2007) Angiotensin (1–7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependant pathways. Hypertension 49: 85–192.
39. Santos R.A. Simões A.C. Maric C. (2003) Angiotensin (1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258–8263.
40. Sastry K.V.H. Moudgal R.P. Mohan J. Tyagi J.S. Rao G.S. (2002) Spectrophotometric determination of serum nitrite and nitrate by copper–cadmium alloy. Analytical Biochemistry 306: 79–82.
41. Singh K. Singh T. Sharma P.L. (2010 a) Angiotensin (1–7)/Mas receptor axis activation ameliorates the changes in fatty acid composition in diabetic rats with nephropathy. J Exp Pharmacol 2: 163–168.
42. Singh R. Singh A.K. Leehey D.J. (2005) A novel mechanism for angiotensin II formation in STZ-diabetic rat glomeruli. Am J Physiol Renal Physiol 288: F1183–F1190.
43. Singh T. Singh K. Sharma P.L. (2010 b) Ameliorative potential of angiotensin1–7/Mas receptor axis in streptozotocin-induced diabetic nephropathy in rats. Methods Find Exp Clin Pharmacol 32: 19–25.
44. Tikellis C. Johnston C.I. Forbes J.M. Burns W.C. Louise M. Risvanis B.J. et al (2003) Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41: 392–397.
45. Tipnis S.R. Hooper N.M. Hyde R. Karran E. Christie G. Turner A.J. (2000) A human homolog of angiotensin converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238–33243.
46. Trinder P. (1969) Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 6: 24–25.
47. Vickers C. Hales P. Kaushik V. Dick L. Gavin J. Tang J. et al (2002) Hydrolysis of biological peptides by human angiotensin converting enzyme-related carboxypeptidase. J Biol Chem 277: 14838–14843.
48. Wang J. Ye S. Wang Q. Kralik P.M. Epstein P.N. (2006) Causes and characteristics of diabetic cardiomyopathy. Rev Diabet Stud 3: 108–117.
49. Weisinger R.S. Stanley T.K. Begg D.P. Weisinger H.S. Spark K.J. Jois M. (2009) Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6 J mice maintained on a high fat diet. Physiol Behav 98: 192–197.
50. Welches W.R. Brosnihan K.B. Ferrario C.M. (1993) A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase. Life Sci 52: 1461–1480.
51. Ye M. Wysocki J. Naaz P. Salabat M.S. Batlle D. (2004) Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice. A renoprotective combination? Hypertension 43: 1120–1125.